PDL BioPharma Completes Regular Quarterly Dividend Payment
PDL BioPharma Completes Regular Quarterly Dividend Payment
September 15, 2011
About PDL BioPharma
PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. Today, PDL is focused on intellectual property asset management, investing in new royalty bearing assets and maximizing the value of its patent portfolio and related assets. For more information, please visit www.pdl.com.
NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.
Contacts:
Cris Larson
PDL BioPharma, Inc.
775-832-8505
cris.larson@pdl.com
Jennifer Williams
Cook Williams Communications, Inc.
360-668-3701
jennifer@cwcomm.org
SOURCE PDL BioPharma, Inc.